北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Glioblastoma multiforme: a review of where we have been and where we are going
作者: Adamson, Cory1,2; Kanu, Okezie O.3; Mehta, Ankit I.1; Di, Chunhui1; Lin, Ningjing4; Mattox, Austin K.1; Bigner, Darell D.1
关键词: GBM ; genetics ; glioblastoma multiforme ; oncogenomics ; signaling cascades
刊名: EXPERT OPINION ON INVESTIGATIONAL DRUGS
发表日期: 2009-08-01
DOI: 10.1517/13543780903052764
卷: 18, 期:8, 页:1061-1083
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: PRIMARY INTRACRANIAL TUMORS ; HIGH-GRADE ASTROCYTOMA ; GROWTH-FACTOR RECEPTOR ; COMPARATIVE GENOMIC HYBRIDIZATION ; PLACEBO-CONTROLLED TRIAL ; THERAPY-ONCOLOGY-GROUP ; PRIMARY BRAIN-TUMORS ; PHASE-III TRIAL ; RECURSIVE PARTITIONING ANALYSIS ; BEVACIZUMAB PLUS IRINOTECAN
英文摘要:

Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GEM patients remains dismal: median survival after diagnosis is about 14 months. Established good prognostic factors are limited, but include young age, high Karnofsky Performance Status (KPS), high mini-mental status examination score, O6-methylguanine methyltransferase promoter methylation, and resection of > 98% of the tumor. Standard treatment includes resection, followed by concurrent chemotherapy and radiotherapy. GBM research is being conducted worldwide at a remarkable pace, with some of the more recent promising studies focused on identification of aberrant genetic events and signaling pathways, tumor stem cell identification and characterization, modulation of tumor immunological responses, combination therapies, and understanding of the rare long-term survivors. Past treatment strategies have failed for various reasons; however, newer strategies in trials today and on the horizon encourage optimism. To help illustrate ′where we have been′ with this fatal disease and ′where we are going′ with contemporary studies, we include in this review a detailed history of Phase III clinical trials for GBM, with a final emphasis on exciting new treatment strategies that offer hope for future GBM therapy.

语种: 英语
WOS记录号: WOS:000268789900002
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56289
Appears in Collections:北京大学临床肿瘤学院_肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Duke Med Ctr, Durham, NC 27712 USA
2.Durham VA Med Ctr, Neurosurg Sect, Durham, NC USA
3.Univ Lagos, Teaching Hosp, Lagos, Nigeria
4.Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Oncol, Beijing 100871, Peoples R China

Recommended Citation:
Adamson, Cory,Kanu, Okezie O.,Mehta, Ankit I.,et al. Glioblastoma multiforme: a review of where we have been and where we are going[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS,2009,18(8):1061-1083.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Adamson, Cory]'s Articles
[Kanu, Okezie O.]'s Articles
[Mehta, Ankit I.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Adamson, Cory]‘s Articles
[Kanu, Okezie O.]‘s Articles
[Mehta, Ankit I.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace